This work aims to evaluate the possible impact of interactions between bevacizumab solutions and an implantable port equipped with a silicone or a polyurethane catheter after infusion through a complete infusion set-up in simulated use conditions. Physico-chemical and structural stability of bevacizumab solution was assessed by visual examination, subvisible particles counting, dynamic light scattering, size exclusion chromatography and ion exchange chromatography. Mechanical properties of the catheters were evaluated by measuring Shore A hardness, strain at break, strain at stress and Young's modulus. The physico-chemical surface state of the catheters was assessed by FTIR-ATR spectroscopy, scanning electron microscopy (SEM) and by water contact angle measurement. The analysis of the bevacizumab solution did not highlight any signs of instability or loss of active substance. Mechanical properties of both materials remained unchanged after the infusion. During material analysis, a decrease in water contact angle observed after infusion and was more pronounced for polyurethane catheters than for silicone, possibly due to bevacizumab adsorption or possible leachable extraction from the materials. Surface modifications were also noted at SEM. This study did not highlight any modifications that could alter the quality of the bevacizumab infusion, nor of the infusion catheter in polyurethane or silicone, despite a modification of surface hydrophilicity. Even if after a single infusion, implantable ports remained safe to use, they aim to be used for several infusion of various drugs during their lifetime, and further studies are needed to assess the impact of repeated infusions.
Introduction
Monoclonal antibodies (mAbs) are therapeutic agents broadly used in the field of oncology [1] . It is known that their use for anti-tumour immunotherapy presents current and future opportunities for the treatment of cancers that conventional chemotherapy cannot bring, with fewer adverse effects. mAbs are immunoglobulins (or immunoglobulins fragments), composed of two heavy chains around 50 kDa and two light chains around 25 kDa, linked by intra or intermolecular interactions building a secondary and a tertiary structure, giving the molecule its tridimensional structure [2] .
Physico-chemical stability and biological activity after reconstitution and dilution of numerous antibodies have already been studied in various containers (rituximab [3] , bevacizumab [4, 5] , infliximab [6] , etc.). Their instability can be generated by different factors, including interactions with the surfaces. Those interactions can cause a conformational rearrangement and aggregation [7] , altered the immunogenic potential [8] or modify biological activity of the antibody [9] . It has been shown that mAbs can interact (adsorption or aggregation) with many surfaces or interfaces, like glass, metallic particles, silica or silicon oils [10] [11] [12] [13] . Even though polymeric-based surfaces ( polyvinyl chloride, silicon, polyurethane) are always found in medical devices used for infusion, and that they are known for interacting with small peptides, like cyclosporine or insulin [14] [15] [16] , their influence upon the stability of mAbs in clinical situations has not been fully studied. Sorption phenomenon can also be a major concern during the infusion process since the drug lost is not administered to the patient and means a loss of effectiveness of the treatment.
Bevacizumab is an IgG1 mAb anti-vascular endothelial growth factor (VEGF) mAb in anti-cancer therapy indicated for the treatment of (in association with other anti-cancer drugs) metastatic colorectal cancer, non-small cell lung cancer or breast cancer [17] . It was chosen as being representative of most of the therapeutic mAbs, as currently, all the therapeutic mAbs are IgG and mostly from IgG1 subtype [18] .
The objective of this study was to quantify bevacizumab and evaluate its physico-chemical stability after a contact with polymers during infusion through a complete set-up including a polyolefin bag, a PVC infusor and an implantable port equipped with a silicone or a polyurethane catheter in simulated use conditions, and to investigate potential topographic, mechanical and physico-chemical material surface modification of the catheters.
Material and methods

Materials
Bevacizumab, Avastin ® 25 mg ml −1 solution for infusion (batch H0191B07, expiry February 2018), was purchased from Roche (Boulogne-Billancourt, France). Sodium chloride 0.9% IV bags were purchased from Fresenius-Kabi (Louviers, France). Titanium implantable ports equipped with a silicone catheter (ref:
0602230CE, batch REAV0473, expiry 08/2021) and a PU catheter (ref: 0605320CE, batch REAU1520, expiry 03/2021) were purchased from Bard Access Systems (Salt Lake City, USA). PVC infusion set (ref: A64, batch 4905, expiry 11/2020) were purchased from Carefusion (Voisins-le-bretonneux, France). Sodium sulfate (Na 2 SO 4 ), disodium phosphate (Na 2 HPO 4 ), sodium azide (NaN 3 ), 4-morpholinoethanesulfonic acid (MES), sodium chloride (NaCl), guanidine hydrochloride (GnHCl), Tris-hydrochloride (Tris-HCl), ammonium carbonate, dithiothreitol (DTT), iodoacetic acid, acetylated trypsin, sodium hydroxide (NaOH), hydrogen chloride (HCl), acetonitrile and trifluoroacetic acid (TFA) were all purchased from Sigma-Aldrich (Saint Quentin Fallavier Cedex, France). All reagents were certified of HPLC grade.
Study design
In order to simulate the infusion of a bevacizumab solution through an implantable port as it is performed in clinical conditions, an experimental apparatus was built as shown in figure 1 . Bevacizumab solutions were diluted to 4 mg ml −1 by addition of the vial content (4 ml) into a 100 ml NaCl IV bag and used right after preparation, and were infused through the infusion set and then through the implantable port during 2 h at a flow rate of 1 ml min −1 as recommended for first-time infusions of bevacizumab. The bath water was maintained at 37°C to reproduce the body temperature, and the infusion set was kept just under the water surface by a metal plate, in order to remain at room temperature. Before infusion, the length of the implantable port's catheter was standardized to 50 cm for both devices.
Bevacizumab solution samples were taken at T0 from the infusion bag, at T20, 70 and 110 min after the infusion set (from the Y withdrawing site of the Huber needle) and at T10, 60 and 120 min at the terminal tip of the catheter. Material samples were collected before any infusion (control) and after a 120 min infusion. A diluent control set-up was also performed by infusing an NaCl solution without bevacizumab through silicone and PU catheters. After 120 min, surface and mechanical properties of control catheters were assessed and compared to material samples collected after contact with bevacizumab.
For both catheters, the whole experimental set-up and the analyses performed at the different analytical times were realized in triplicate, except if mentioned otherwise.
Analyses performed on the bevacizumab solutions
Samples were analysed in triplicate and diluted with 0.9% NaCl solutions to 0.4 mg ml −1 before analysis, except for subvisible particles counting, peptide mapping and second-derivative Fourier transform infrared spectroscopy (SD-FTIR). The analytical methods used in this study were developed and used according to the international guidelines for the characterization of mAbs, and are capable of highlighting changes in antibody structure (see electronic supplementary material).
2.3.1. Physical stability analysis 2.3.1.
Visual inspection
The solutions were visually inspected under a white light in front of a matt black panel and a non-glare white panel. Aspect and colour of the solutions were noted, and a screening for visible particles, haziness or gas development was performed.
Turbidimetry
Turbidity was evaluated by measuring the absorbance of the bevacizumab solutions at 320 and 350 nm using a spectrophotometer UV/VIS/NIR Jasco V-670 (Jasco France, Bouguenais, France) equipped with a single monochromator, a deuterium lamp (range 190-350 nm) and a halogen lamp (range 330-2700 nm). The results were analysed using the provided software (Spectra manager II). An increase in the calculated aggregation index (AI) compared to the D 0 reference is indicative of an increase in samples turbidity. Equation (2.1): the estimation of turbidity by calculation of AI. A corresponds to absorbance at specified wavelengths (280 and 350 nm)
Â 100: ð2:1Þ An AI value < 10 was considered to be acceptable [19, 20] .
Subvisible particles counting
Subvisible particle counting was performed on an HIAC Royco 9703 (Hach Lange, Noisy le Grand, France) equipped with an HRLD 400 EC detector. For each triplicate, four successive measurements were carried out on a volume of 2 ml, and the first run was discarded. The results were expressed as the number of particles larger than 10 and 25 µm, per millilitre of solution.
Nanoparticle size determination
Dynamic light scattering (DLS) allows the estimation of the size of protein aggregates between 0.3 and 10 µm. The particle size is obtained from the variation of intensity of light scattering due to Brownian motion of particles. Particle size was determined on 1 ml of each triplicate in clear glass cells by DLS measurements, using a Zetasizer Nano ZS (Malvern Instruments SARL, Orsay Cedex, France). Each sample was automatically screened three times. The obtained size distribution was presented by percentage of intensity and must conform to reference (D 0 ) profiles. A variation in size of less than 3 nm of the main peak's hydrodynamic radius was considered as being acceptable. In parallel, the apparition of a peak different from bevacizumab main peak for which intensity percentage was superior to 10% was considered as being unacceptable.
Size exclusion chromatography
Size exclusion chromatography (SEC) allows the evaluation of mAb aggregation or fragmentation. The chromatographic separation was performed by liquid chromatography (LC), using an LC-2010-A HT with integrated controller, pump, autosampler, oven and UV-VIS dectector (Shimadzu Corporation, Marne la Vallée, France). Two LC separation columns TSK-GEL ® G3000SWXL columns (7.8 mm × 30 cm × 5 µm, TOSOH Bioscience), purchased from Interchim (Montluçon, France) were used, mounted in series. A sample volume of 100 µl was injected into the system and then eluted using an isocratic flow (Na 2 SO 4 0.1 M Na 2 HPO 4 0.1 M and 0.05% m/w NaN 3 in water, buffered at pH 7) at a flow rate of 0.6 ml min −1 , at a set temperature of 25°C. The detection wavelength was set up at 280 nm. The obtained SEC chromatograms must conform to reference (D 0 ) SEC chromatogram (monomer ≥ 97%). However, apparition of other species (oligomer or fragment) was followed, when applicable. Inc., Radiometer, SAS, Neuilly Plaisance). pH measurements were considered to be acceptable if they did not vary by more than 1 pH unit from initial measure. Osmolality measurements are to be interpreted with regard to the potential modification of other parameters and, for the purpose of this study, were considered to be acceptable if they did not vary by more than 10 mosmol kg −1 from D 0 values.
Cation exchange chromatography
Cation exchange chromatography is used to separate different isoforms of bevacizumab. The chromatographic separation was performed by LC, using an LC-2010-AHT with integrated controller, pump, autosampler, oven and UV-VIS detector (Shimadzu Corporation, Marne la Vallée, France). All analyses were performed on a TSKgel CM-STAT column (4.6 mm × 100 mm × 7 µm, TOSOH Bioscience), purchased from Interchim (Montluçon, France). Buffer A was prepared with 20 mM MES, and buffer B was prepared with 20 mM MES, 0.5 M NaCl. For each buffer, the pH was adjusted to 6.5 using 1 N NaOH solution. The injected sample volume was of 100 µl and elution parameters were the following: flow rate of 1 ml min −1 using a gradient composed of 98% of phase A and 2% of phase B reaching 85% phase A and 15% phase B in 30 min, then 10 min of equilibrium was observed between each analysis. Analysis temperature was set at 35°C. The detection wavelength was set up at 280 nm. The obtained cation exchange chromatography (CEX) chromatograms must conform to reference (D 0 ) CEX chromatogram. The distribution of each ionic variant was expressed in percentage of total area under the curve (AUC). Any variation under 3% was considered to be acceptable.
Structural analyses 2.3.3.1. Peptide mapping
Peptide mapping allows the study of bevacizumab's primary structure. Five hundred microlitres of the solution (250 µl for the 2 mg ml −1 solutions) were denatured with GnHCl (final concentration 6 M) in 0.119 M Tris-HCl buffer at pH = 8.5 and reduced with 2 mM DTT. Denaturation and reduction were performed together for 60 min at 37°C. Samples were then alkylated by 50 mM iodoacetic acid for 15 min at room temperature protected from light. Tris-HCl buffer was removed by using a spin filter 10 kDa molecular weight cut-off (Millipore, Molsheim, France). After 20 min centrifugation at 4000 r.p.m., supernatant was completed up to 3.5 ml with 100 mM ammonium carbonate buffer ( pH = 7.6). Spin filters were centrifuged again 20 min at 4000 r.p.m. The digestion step was performed with an acetylated trypsin ratio 1 : 20 (trypsin/bevacizumab, weight/weight) for 14 h overnight at 37°C. Before chromatographic analysis, samples were recovered from digestion step and completed to 400 µl with 0.1% TFA in water. The reaction was quenched by storing royalsocietypublishing.org/journal/rsif J. R. Soc. Interface 16: 20180721 samples at 5°C inside the refrigerated autosampler, and 20 µl of each sample was injected into the column.
The chromatographic separation was performed by LC, using an LC-2030C with an integrated controller, pump, autosampler, oven and UV-VIS dectector (Shimadzu Corporation, Marne la Vallée, France). The separation was performed on a C18 Nucleosil column (250 mm × 3 mm, 5 µm, Macherey Nagel, France). The mobile phase was composed of 0.1% TFA in water ( phase A) and 0.09% TFA in acetonitrile ( phase B). Elution started with a gradient 95% phase A and 5% phase B which was increased up to 60% phase A and 40% phase B in 140 min. The flow rate was set to 1 ml min −1 and column oven temperature at 40°C. The detection wavelength was set up at 215 nm. A post-run treatment was done by subtracting the chromatogram of the trypsin solution.
The obtained peptide mapping chromatograms must conform to reference (D 0 ) chromatogram. Minor and unreproducible variations in the peptide mapping profile (e.g. slight retention time variations, intensity variations) were considered to be acceptable. Major reproducible differences, like the appearance or disappearance of a peak, were considered to be unacceptable.
Second-derivative Fourier transform infrared spectroscopy
The secondary structure of bevacizumab was monitored by second-derivative FTIR in amide I region (1600-1700 cm −1 )
using an Avatar 320 (Nicolet, Thermo Electron, Courtaboeuf Cedex, France) equipped with a transmission cell with 25 mm BaF 2 windows. All acquisitions were treated with Omnic software. For FTIR analysis, samples of each concentration were concentrated up to 40 mg ml −1 using a spin filter 10 kDa molecular weight cut-off (Millipore, Molsheim, France). The obtained FTIR spectra must conform to reference (D 0 ) profiles. A shift in maxima's and minima's wavenumbers inferior to 2 cm −1 was considered to be acceptable.
Second-derivative UV spectroscopy
Tertiary structure was studied by second-derivative UV spectroscopy. All spectrums were acquired on a Spectrophotometer UV/VIS/NIR Jasco V-670 (Jasco France, Bouguenais, France), using 1 cm pathlength quartz cuvettes and the measurement wavelength range was set between 250 and 320 nm. All acquisition data were treated with Spectra manager II software. The obtained second-derivative ultraviolet spectra must conform to reference (D 0 ) spectra. A shift in maxima's and minima's wavelengths inferior to 2 nm was considered to be acceptable.
Total protein quantification
Protein content per vial was estimated by measuring absorbance at 280 nm [21] of bevacizumab solutions. All data were acquired on a spectrophotometer UV/VIS/NIR Jasco V-670 (Jasco France, Bouguenais, France), using 1 cm pathlength quartz cuvettes. Protein content was calculated using the Beer-Lambert Law.
Protein content was considered to be acceptable when between 95 and 105% of theoretical concentration.
Analyses performed on the catheters 2.4.1. Mechanical studies
The mechanical characteristics of catheters was determined using a tensile test (MTS 20 M) and a hardness durometer. The tensile test was carried out on the tubular medical devices by taking into account the geometry of the samples. The mechanical properties of the catheters were assessed form the stress-strain curves. Young's modulus, the stress and strain at break have been evaluated, each value being the result of a minimum of three measurements performed each time on each triplicate.
The Shore A hardness value determination was performed with an analogue testing instrument after a dwell time of 3 s.
Surface characterization
The physico-chemical properties of a surface may influence interfacial reactions, and its characterization is important in providing information on the chemical structure or through parameters such as the hydrophilic/hydrophobic ratio. Among the number of techniques developed to study surfaces, two common surface characterization techniques for polymers were used: the contact angle measurements and the attenuated total reflectance FTIR (ATR-FTIR) completed by scanning electron microscopy (SEM).
Contact angle measurements were performed on the catheters to characterize the hydrophilicity/hydrophobicity behaviour of the surfaces before and after infusion of bevacizumab. The sessile drop method was used: a small drop of deionized water (4 µl) was laid down on the surface of the catheters and analysed with a contact angle measuring system (Krüss Drop Shape Analyzer DSA 14) involving angle measurements in a normal plane. During image analysis, the water contact angle between the baseline of the drop and the tangent at the drop boundary was calculated with the DSA software.
ATR-FTIR measurements were carried out on the surface of catheters using a Nicolet 6700 spectrometer equipped with an ATR device (diamond crystal). Spectra were obtained in the 4000-400 cm −1 region, using 30 scans and 4 cm −1 resolution.
Before each measurement, a blank spectrum was obtained to eliminate the effect of humidity and carbon dioxide in air. The surfaces were characterized by SEM using a Zeiss Supra 55 VP (Carl Zeiss SMT, Nanterre, France) SEM after gold sputtering with secondary emission and SE detector. The accelerating voltage and the working distance were, respectively, of 1 kV and between 5.5 and 6.5 mm (image-dependent). For each studied sample, multiple images at magnifications ranging from 1000 to 50 000 were taken, representing at least three different zones.
Data analysis: acceptability criteria
The study was conducted following methodological guidelines issued by the International Conference on Harmonisation for stability studies (ICH guidelines for stability [22, 23] and specifications for Biotechnological/Biological products [24] ), Bardin et al. [25] , the European Pharmacopeia [26] and recommendations issued by the French Society of Clinical Pharmacy (SFPC) and the Evaluation and Research Group on Protection in Controlled Atmosphere (GERPAC) [27] and the French Society and European Society of Oncology Pharmacy [28] . NHS recommendations [29] were also taken into account.
Results
Bevacizumab solutions 3.1.1. Visual inspection
Solutions in the infusion bags were limpid and colourless. During the study, visual aspect remained unchanged at both sampling site (after the infusion set and after the catheter).
Turbidity
Turbidity was assessed by calculating AI. At T0, AI was, respectively, 0.50 ± 0.13% and 0.42 ± 0.10% for the PU and silicone condition (mean ± s.d.). No variation of more than 0.45% was observed during the study, thus remaining within acceptability criteria.
Subvisible particles counting
The counting of subvisible particles superior to 10 and 25 µm is presented in figure 2 . A global but not significant decrease royalsocietypublishing.org/journal/rsif J. R. Soc. Interface 16: 20180721 overtime was observed for both types of catheters (silicone and polyurethane).
Dynamic light scattering
Nanoparticle size was estimated by DLS. At D 0 , the mean hydrodynamic diameter was of 11.6 ± 2.6 nm, and no variation of more than 0.29 nm was observed during any of the studies, thus remaining within acceptability criteria.
Size exclusion chromatography
A separation of different bevacizumab species was performed by SEC ( figure 3) . Five products were highlighted, including three different high molecular weight products (HMWP), respectively, at elution times (e.t.) of 16.1, 20.6 and 22.4 min, monomeric form at e.t. of 27.4 min and fragments at e.t. of 32.9 min. At the initial state, the AUC of the monomeric form represented 97.77 ± 0.34% of total AUC, fragmented form was 0.09 ± 0.08% and HMWP were, respectively, of 0.29 ± 0.24%, 0.15% ± 0.02% and 1.69 ± 0.08% (table 1) . Monomer percentage of total AUC did not vary by more than 0.21%. Throughout the study, the monomer quantification met acceptability criteria.
pH/osmolality
At T0 (bevacizumab solutions in the infusion bags), pH was of 6.26 ± 0.06 and osmolality of 285.25 ± 1.15 mosmol kg and osmolality remained within acceptability criteria limits, as no variation of more than 0.1 pH unit and 2.0 mosmol kg −1 was observed.
Cation exchange chromatography
At the initial state, five variants were detected in the bevacizumab solution. Peak percentages (table 2) of total AUC at T0 were of 4.04 ± 0.83%, 9.89 ± 0.81%, 9.48 ± 1.20%, 72.96 ± 2.55% and 3.63 ± 0.98% for, respectively, peaks 1-5 (n = 3, mean ± s.d.). Throughout the study and for both conditions, percentage of total AUC of each peaks never varied by more than ±1.36% and thus remained within acceptability criteria.
As an example, charge variants separation by CEX of bevacizumab solution infused through the apparatus with a polyurethane catheter sample is presented in figure 4 .
Peptide mapping
The peptide map of bevacizumab samples from every analytical time was acquired and compared to the T0 reference peptide map. No significant variation was highlighted for any condition. As an example, the comparison of the peptide map of bevacizumab solution after 120 min through a PU and silicone catheter is shown in figure 5 and is consistent with data obtained for the other time points (after 10 and 60 min infusion through the catheter). The peptide map highlighted no significant variations.
Second-derivative infrared spectroscopy
Second-derivative FTIR spectra of bevacizumab solutions after a 120 min infusion through the PU and silicone catheters are compared to the spectra in the initial state in figure 6 . Maxima and minima of each peak were studied at every analytical time and compared to the initial state reference; none of them is shifted by more than 1 cm 
Second-derivative UV spectroscopy
Second-derivative UV spectra of bevacizumab solutions after a 120 min infusion through PU and silicone catheter are compared to the spectra in the initial state in figure 7 . Maxima and minima of each peak were studied at every analytical time and compared to the initial state reference, none of them shifted by more than 0.4 nm.
Total protein content
The quantitation of total protein content was performed by measuring absorbance at 280 nm at each analytical time for both conditions. Figure 8 shows the percentage of variation (n = 3; mean ± s.d.) of the bevacizumab solution after infusion through PU and silicone catheter from solution in the infusion bag before infusion (T0). The observed variation always remains within the 95-105% range.
Total protein content was also assessed in samples withdrawn between the infuser and the implantable port, Table 1 . Percentage of total AUC of each bevacizumab size variants separated by SEC after infusion through PU or silicone catheter of an implantable port (mean ± s.d., n = 3. Except for infusion bags samples for which n = 6). 
Polyurethane and silicone catheters 3.2.1. Mechanical properties
As presented in figure 9 , the mechanical properties of both catheters were not affected by a bevacizumab infusion or a 0.9% NaCl infusion (electronic supplementary material, figure SA). Young's modulus (figure 9a) of the silicone and PU catheters exhibited means values of about 3.6 and 9.5 MPa, respectively. Logically, the strain (figure 9b) and stress (figure 9c) at break-point of both samples are notably different. The three mechanical properties assessed by the tensile test indicate a stiffer and less ductile behaviour of the PU medical device compared to the silicone one.
In accordance with the tensile test results, the Shore A hardness (figure 9d ) value measured on the PU medical device is greater than the one obtained for the silicone catheter, a difference of about 20% was noted (85 versus 71 Shore A).
Surface characterization
Wettability results presented in figure 10 show a water contact angle of, respectively, 94.2°and 97.1°on PU and silicone devices before infusion. No difference in water contact angle was noted after infusion of a 0.9% NaCl solutions. But, the bevacizumab infused catheters exhibits lower water contact angle values compared to the control ones. After infusion, a decrease in contact angle was observed for both PU and silicone catheter. However, a statistically significant decrease royalsocietypublishing.org/journal/rsif J. R. Soc. Interface 16: 20180721 was more pronounced for the PU catheter than for the silicone catheter (20°and 12°, respectively; t-test, p = 0.041).
ATR-FTIR spectra presented in figures 11 and 12 suggest that the surface structure of the medical devices was not altered by the infusion of bevacizumab. The spectra collected for the control or the bevacizumab infused catheters are close to identical.
The FTIR analyses revealed that the investigated PU catheter consists of aromatic polyurethane chains (hard segments) and polycarbonate chains (soft segments). They also suggest that the silicone catheter is mainly based on poly(dimethyl-siloxane).
The FTIR spectroscopy identified barium sulfate (BaSO 4 ) in both catheters (bands located at 1187, 1123, 1078, 987, 638 and 611 cm −1 ).
An analysis of the inner surface structure of the PU and silicone catheters was performed by SEM. Comparison of the surface state before and after infusion for both conditions is shown in figure 13 . 
Discussion
This work evaluated whether the infusion of a bevacizumab solution through an implantable port had an impact or not upon drug stability or caused an alteration of the infusion devices' properties. After a single infusion, the physico-chemical and structural stability of bevacizumab in solution remained unchanged. Material characterization showed expected differences between silicone and PU in terms of rigidity, but none of the material's mechanical properties were modified by the infusion. However, surface state variations were highlighted by water contact angle measurements and SEM.
Bevacizumab is an mAb from the IgG1 subtype and is, therefore, representative of most of the therapeutic mAbs currently available on the market. It was of interest to assess potential variation in this mAb stability with this type of setup as bevacizumab is likely to be infused via implantable ports and a variation or degradation in the administered dose could alter the efficacy of the therapy. Bevacizumab physico-chemical stability was expected to a certain extent, as bags were reconstituted following the manufacturer instructions and were used right after reconstitution. mAbs are known to be stable at 25°C and up to 40°C for several days when in contact with various inert materials like glass vials. However, the impact of different tubing materials on mAb stability has not been well documented. The silicone oil used is known to cause aggregation with mAbs, especially with bevacizumab; therefore, particle formation was particularly monitored. Our study did not highlight any significant differences between polyurethane and silicone concerning subvisible particles assessed by light obscuration, but a decrease in subvisible particles overtime was noted. Soluble aggregates from the reconstitution step might have been solubilized with time leading to this decrease. Therefore, due to the low volume of solution available for each sample, light obscuration analysis were performed at the technical limit of the machine leading to an important analytical variation between samples. However, this result was confirmed by the AI measurement which remained unchanged along the study. For most mAbs, it is recommended that infusion occurs through an infusion set equipped with a 0.22 µm online filter which is able to limit the amount of particles. DLS was used to assess the hydrodynamic diameter of bevacizumab molecules and no variation from the initial state was noted at any time. This result is in agreement with the absence of HMWP or fragment observed with the SEC separation; indeed, the monomeric form remained constant throughout the study. All the analytical techniques indicated that bevacizumab remained physically stable during the infusion time. Chemical stability was assessed by measuring pH, osmolality and CEX separation in LC. CEX chromatography is used to study the different charge variants of bevacizumab. Proportions of each variant were estimated by expressing their respective percentage of total AUC. Throughout the study, variant proportions remained unchanged. Osmolality and pH were measured as they are critical parameters for intravenous injection, but ionic strength and pH variation can also be involved in protein aggregation mechanism [30, 31] . 
( f ) Figure 13 . SEM images ×5000 of a reference silicone catheter (a), a silicone catheter after 0.9% sodium chloride infusion for 120 min (b), a silicone catheter after 4 mg ml −1 bevacizumab infusion for 120 min (c), a reference PU catheter (d ), a PU catheter after 0.9% sodium chloride infusion for 120 min (e) and a PU catheter after 4 mg ml −1 bevacizumab infusion for 120 min ( f ).
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To characterize the structural properties, the primary, secondary and tertiary structures of bevacizumab were assessed, respectively, by peptide mapping, SD-FTIR and SD-UV. None of those analyses highlighted any change at any time of the study. This structural analysis was also consistent with the conclusions reached concerning physical and chemical stability, as physico-chemical and structural modifications are often related during the degradation process of mAbs.
The global amount of bevacizumab was assessed by measuring total protein content, and specific monomeric bevacizumab was quantified by measuring AUC of the monomeric form separated by SEC to provide a more specific information. None of those analytical techniques were able to highlight any variation from the initial concentration in the infusion bags. Sorption phenomena could have decreased the amount of bevacizumab available. Adsorption was the only suspected phenomenon, given the steric hindrance of an mAb, theoretically excluding absorption. One of the limiting factors when a molecule is adsorbed onto a material is the contact area which reaches a sort of saturation state. However, bevacizumab was infused at a concentration of 4 mg ml −1 , which is the recommended concentration in clinical use but is a quite high concentration. So even if bevacizumab had adsorbed onto the infusion set or catheter tube, the loss of bevacizumab could have been too small proportionally (when compared with the initial bevacizumab quantity) to be significant. Based on those results, adsorption of bevacizumab onto PU and silicone catheter can be considered as clinically negligible for the tested conditions and apparatus, but cannot be excluded based only on bevacizumab quantification. The infusion of bevacizumab is safe and the right dose is administered to the patient. For comparison, the infusion bags for blinatumomab (Blincyto ® ) administration must be previously prepared before drug dilution using a protective coating solution ( polysorbate 80) in order to avoid unacceptable protein adsorption [32] . Indeed, as blinatumomab must be administered at a concentration of 0.160 µg ml −1 , even a slight protein loss due to adsorption would induce a proportionally significant decrease in concentrations, possibly leading to clinical inefficacity.
SEM provided information about the catheter surface state. After a single bevacizumab infusion of 120 min, PU catheters presented a pleated aspect, while silicone catheters remained unchanged. This could be explained by topographic surface modifications of the PU surface, perhaps linked to the migration of certain components. Extractables and leachables are known molecules that could be released in 0.9% NaCl solutions after infusion [33] and this migration could be an alternative explanation to the surface state modification that was observed with the PU catheter. Even though the change in PU surface aspect was not related in any change in mAb stability, a recent study [34] has shown that PU catheters were more prone to thrombotic and infectious complications than silicone catheters. This observation could be compatible with our finding, as the pleated aspect could lead to an increase in surface contact area that could increase the ability of bacteria to fix onto the catheters and thus could facilitate the bacterial proliferation.
The surface pleated aspect of the PU catheter may also possibly be a consequence of a mechanical stress involved by BaSO 4 release. BaSO 4 is usually added to the catheter materials as radio-opaque additive, which is required for any medical products that can be potentially incorporated into the patient [35] . Other authors reported that the presence of BaSO 4 is responsible for cracks and notches observed on the PU catheter surface after incubating periods with chemiotherapy agents [35] . They concluded that the BaSO 4 particles probably break out the polymer matrix of the incubated PU catheter, dependent from the environment they are flushed away. Verbeke et al. [36] also described that the irregularities observed on PU catheter surface results from the release of BaSO 4 and linked those surface defects to subsequent increased catheter-related infections.
In the absence of any apparent physico-chemical degradation of the investigated PU catheter consecutive to bevacizumab infusion, it cannot be excluded that its surface pleated aspect may be cause by mechanical triggered (BaSO 4 release).
Mechanical characteristics were assessed by tensile testing (strain and stress at break) and Shore A hardness measurements. Analyses highlighted, as expected, that silicone was more ductile while PU was stiffer, but no variation was noted between catheters before and after infusion.
Wettability results indicated that the surfaces of both catheters before infusion are slightly hydrophobic. Results reported that the bevacizumab infused catheters presented lower water contact angle values compared to the control ones. In both cases, this change in water angle suggests an evolution from a slight hydrophobic behaviour to a more hydrophilic character of the catheter surface after infusion of bevacizumab; the effect being more pronounced for PU. Surface state is one of the major points related to the biocompatibility of a medical device. A modification of the hydrophilic or hydrophobic character of a medical device surface could be related to changes in its biocompatibility and even cause adverse effects overtime. A recent study by Tortolano et al. [37] highlighted that during polymer ageing, some PMMA-based ocular lenses could release additives leading to a modification in hydrophilicity of the implants surface and a potential cornea opacification. They also highlighted changes in the adhesion of a protein (fibronectin) related to a change in biocompatibility. Other recent studies have shown that the exsudation of antioxidant and ultraviolet light absorbers modified the surface topography, water contact angles and its chemical composition without having a significant impact on cytocompatibility, short-term inflammatory reaction and haemocompatibility while it influenced cell adhesion and possibly bacterial adhesion [38, 39] . Thus, the change in water contact angle reported in our study seems only to provide qualitative information indicative of a modification of the topography or the surface chemistry of the medical device's inner surface (possibly linked to the migration of additives), without necessarily having an impact on the biocompatibility or the safety of the device.
Even though adsorption of bevacizumab onto PU and silicon catheters is clinically negligible, it cannot be excluded that such a minor effect may somehow affect the surface wettability, which might partly explain the wetting effect observed.
An additional approach, slightly connected to the reported SEM observations, would involve a possible leachable extraction from PU catheters, which may also be in agreement with the difference in water contact angle evolution reported for the two catheters (i.e. a more wetting effect involved for PU surface). However, such a hypothesis does not in itself explain the change of wettability observed for the silicones surfaces. An alternative explanation can be related to the possibility of BaSO 4 release from the catheters, which may impact its uppermost surface morphology and consequently the water contact angle.
The ATR-FTIR spectra gave an overview of the surface composition, all bands belonging to PU or Silicone whether at initial or final state. No sign of bevacizumab adsorption or of extractable/leachable compounds was highlighted with this analytical technique, certainly due to the low sensitivity of ATR-FTIR.
This study assessed differentially the interactions between bevacizumab and an implantable port equipped with PU or silicone catheter. The infusion of a 0.9% NaCl control solution highlighted that material's surface alteration and difference in wettability were related to the bevacizumab or one of the medication excipients. However, all experiments were performed with unused medical devices. The advantage of our protocol is that it allowed the conditions to be standardized and to test the interaction of the bevacizumab solutions and material in itself, and not be influenced by potential material ageing. In clinical conditions, implantable ports can be used for up to 1 year with multiple drugs. Even if after a single bevacizumab infusion, the PU or silicone of the catheter did not seem to be altered, slight modifications were observed and could have a more significant impact after repeated injections. In order to evaluate the clinical impact of long-term clinical use, additional experiments should be conducted, for example, using cyclic testing in an identical experimental set-up, or on explanted catheters, but to be relevant, such a study would have to include many patients in order to take into account the greater sources of variability. Our preliminary results provide information about the initial state of the catheters and could act as a reference for such clinical studies. After a long-time implantation, the role of additives like BaSO 4 has been shown, as BaSO 4 particles were flushed away from polymer matrix and may be responsible for notch formation [35] . An adsorption phenomenon during repeated infusion could lead to the formation of additional drug layers and a potential aggregation of the mAb. Therefore, analytical techniques employed to characterize the interface between catheters and bevacizumab were not able to highlight directly the sorption process and allowed us only to suggest it. Biological activity was not studied since the usage recommendations were respected. However, in the absence of any physical, chemical or structural modifications, it seems unlikely that the biological activity could have been modified.
Conclusion
Physico-chemical and structural properties of bevacizumab in saline solutions were not modified after a simulate infusion through an infusion set connected to a titanium implantable port with silicone or polyurethane catheter. Slight material modifications provided interesting information that suggested a possible sorption effect of bevacizumab upon the PU and silicone infusion tubes. However, overall this effect was very limited and of very unlikely clinical impact.
Data accessibility. The data that support the findings of this study will be made available by the corresponding author upon request.
